How to Appeal an Aetna Prior-Authorization Denial for Weight-Loss Medication

By the PriorAuthAppeal editorial team · Sources cited · Independent of Aetna

Last reviewed 2026-05-06

Aetna covers Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), and Zepbound (tirzepatide) under its Clinical Policy Bulletin (CPB): Anti-Obesity Pharmacotherapy when a member has a BMI ≥ 30 kg/m², or a BMI ≥ 27 kg/m² with at least one recognized weight-related comorbidity, has completed or cannot tolerate a 3-month phentermine trial, and is enrolled in a concurrent lifestyle modification program. If Aetna denied your prior-authorization request, that denial is not the end of the road — you have up to 180 days to appeal, two internal appeal levels, and access to independent external review. This guide walks you through every step.

At a glance

• Covered drugs: Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), Zepbound (tirzepatide)
• BMI threshold: ≥ 30 kg/m², OR ≥ 27 kg/m² with at least one recognized comorbidity
• Recognized comorbidities: Type 2 Diabetes, Hypertension, Dyslipidemia, Coronary heart disease, Obstructive sleep apnea, Non-alcoholic fatty liver disease
• Step-therapy requirement: Documented 3-month trial of phentermine, OR documented inability to tolerate phentermine, OR documented medical contraindication — physician notes required
• Lifestyle program requirement: Concurrent enrollment in a reduced-calorie diet and increased physical activity program at the time of GLP-1 initiation
• Appeal deadline: 180 days from the date of the denial notice
• Internal appeal levels: 2 (first-level, then second-level/expedited if needed)
• External review: Available after internal appeals are exhausted

How Aetna decides whether to cover GLP-1 medications

Aetna's coverage decision is governed by its Clinical Policy Bulletin (CPB): Anti-Obesity Pharmacotherapy, last updated February 2026, available at aetna.com/cpb/medical/data/700_799/0040.html. The CPB sets four criteria that must all be satisfied simultaneously — miss any one of them and the request will be denied.

The first is the BMI threshold. Your most recent recorded BMI must be at least 30 kg/m², or at least 27 kg/m² if you have at least one weight-related comorbid condition. Aetna's recognized comorbidities for the lower threshold are Type 2 Diabetes, Hypertension, Dyslipidemia, Coronary heart disease, Obstructive sleep apnea, and Non-alcoholic fatty liver disease. A diagnosis of any one of these is sufficient to qualify at the 27 threshold — you do not need multiple conditions.

The second criterion is step therapy. Aetna requires evidence that you already tried phentermine for at least three months and it either failed to produce adequate results or caused side effects you couldn't tolerate — or that phentermine is medically contraindicated for you. Phentermine is contraindicated for patients with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or certain psychiatric medications. Physician notes documenting the trial outcome or the specific contraindication reason must be included in the prior-authorization submission.

Third, you must be enrolled in — not merely planning to join — a concurrent lifestyle modification program. Aetna defines this as a reduced-calorie diet combined with increased physical activity, active at the time the GLP-1 prescription is initiated. Referral records, dietitian visit notes, or a structured program enrollment confirmation all serve as documentation.

Fourth, Aetna will deny the request if you have a personal history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2 (MEN-2), or severe pancreatitis — these are safety contraindications to GLP-1 receptor agonists as a class, and no appeal will overcome them.

What makes Aetna's policy distinct from other insurers

Aetna's phentermine step-therapy requirement is more explicit and narrower than many competitors. Most commercial insurers that impose step therapy accept any prior trial of a prescription weight-loss agent — orlistat, topiramate/phentermine extended-release, or bupropion/naltrexone. Aetna's CPB specifies phentermine alone, which means a prior trial of a different anti-obesity medication does not satisfy the requirement unless your physician documents why phentermine specifically was contraindicated. If your previous prescriber tried you on, say, Contrave, but never tried phentermine, Aetna will likely still issue denial code N-431 (step therapy required) — and the appeal must address phentermine specifically, not anti-obesity pharmacotherapy in general.

Aetna's comorbidity list is also more specific than many plans. Six conditions are explicitly named — Type 2 Diabetes, Hypertension, Dyslipidemia, Coronary heart disease, Obstructive sleep apnea, and Non-alcoholic fatty liver disease. Conditions that other insurers sometimes accept — such as osteoarthritis, polycystic ovary syndrome (PCOS), or major depressive disorder — do not appear in Aetna's CPB. If your qualifying comorbidity is PCOS or osteoarthritis, your appeal must make a clinical argument linking that condition to metabolic risk, and success is less certain absent explicit CPB language. Document any of the six listed conditions prominently.

A third distinguishing feature is the concurrency requirement for the lifestyle program. Some insurers accept a prior or completed lifestyle program; Aetna requires the program to be active at the time of GLP-1 initiation. If your program concluded six months ago and you haven't re-enrolled, that gap can generate a denial even when every other criterion is met.

The most common reasons Aetna denies these requests

Denial code CO-50 (not medically necessary) is Aetna's most frequently issued code for GLP-1 requests. It means the reviewer concluded that the submitted documentation did not satisfy one or more of the CPB criteria. The fix is almost always better documentation rather than a fundamentally different clinical picture.

Denial code N-431 (step therapy required) means Aetna's records show no phentermine trial on file. This is often a documentation failure rather than a clinical one — the trial happened but no physician note quantifying the outcome or the contraindication was submitted.

Denial code N-130 (consult plan benefits) typically means the GLP-1 is excluded from the member's specific benefit tier — a different problem from a clinical denial. This code warrants a call to the member services number on your insurance card before drafting a clinical appeal; if the drug is categorically excluded from your plan, the avenue is a coverage exception request or a plan-level grievance rather than a standard prior-authorization appeal.

How to address each denial reason

CO-50 appeals should open by restating every CPB criterion and attaching a document that explicitly satisfies each one. Your physician's letter should quote the BMI measurement with date, name the comorbidity and its ICD-10 code, describe the phentermine trial outcome in clinical terms ("patient discontinued phentermine at week 8 due to palpitations and blood pressure elevation"), and confirm current lifestyle program enrollment with dates.

N-431 appeals need a single focused document: a physician attestation letter that either (a) describes the phentermine trial — drug, dose, duration, specific outcome or adverse event — or (b) lists the medical contraindication to phentermine with supporting clinical evidence such as a cardiology note, ECG result, or medication list showing a drug interaction. Be precise. "Patient could not tolerate" without detail will not satisfy the documentation requirement.

N-130 appeals require a different path. Call member services first. If the exclusion is a plan-level formulary decision, ask specifically whether a "coverage exception" or "step exception" process exists and get the form in writing. If you are in an employer-sponsored plan, your HR benefits coordinator may be able to request a plan amendment.

Federal and state laws that protect your right to appeal

ACA Section 1557 prohibits discrimination in health programs receiving federal financial assistance and requires that coverage decisions be based on clinical evidence rather than categorical exclusions. If Aetna denied your claim on grounds unrelated to the published CPB criteria, Section 1557 provides a basis for complaint to the Department of Health and Human Services Office for Civil Rights.

ERISA Section 503 (codified at 29 CFR 2560.503-1) applies if you receive health insurance through an employer-sponsored plan. It requires Aetna to provide a full written explanation of any adverse benefit determination, including the specific plan provisions and clinical rationale relied upon. If your denial letter does not cite a specific CPB criterion, Aetna is technically in violation of the disclosure requirements under 29 CFR 2560.503-1, and you can cite that procedural defect in your appeal letter. ERISA also mandates that Aetna decide your first-level appeal within 30 days for pre-service claims.

Aetna's published Member Rights and Responsibilities independently guarantees two internal appeal levels and access to independent external review once internal remedies are exhausted. This is separate from any statutory right — it is a contractual commitment. If Aetna fails to respond within the timeframe its own member rights documentation specifies, the claim may be deemed an adverse determination you can escalate immediately.

What a strong appeal letter contains

The single most effective appeal letter is short, structured, and evidence-anchored. Begin by citing the denial code and the specific CPB criterion Aetna says was not met. Then present your counter-evidence criterion by criterion — don't write a narrative; address each gate sequentially.

The clinical evidence that most strengthens a GLP-1 appeal includes:

• A physician or NP letter on practice letterhead that quotes the patient's BMI with measurement date and the ICD-10 code for the qualifying comorbidity
• Chart notes documenting the phentermine trial, including start date, dose, duration, and reason for discontinuation — or a contraindication letter with supporting clinical evidence
• Proof of lifestyle program enrollment: a dietitian referral, program enrollment confirmation, or clinic visit notes dated within 90 days
• A reference to AACE/ACE Comprehensive Clinical Practice Guidelines (Garvey et al., Endocr Pract. 2023), which establish GLP-1 receptor agonists as a first-line pharmacotherapy option for patients with BMI ≥ 30 or ≥ 27 with comorbidity
• A reference to ADA Standards of Care 2025, Section 8, which recommends GLP-1 receptor agonists for patients with Type 2 Diabetes and obesity as a weight-management strategy with cardiovascular benefit
• The specific denial code and a statement that the documentation now supplied directly satisfies the criterion cited in that code

Timeline: what happens after you submit your appeal

Aetna must acknowledge receipt of your internal appeal promptly and issue a first-level decision within 30 days for pre-service (prior-authorization) appeals. You have 180 days from the denial notice date to file your first-level appeal — do not wait. The clock runs from the date on the denial letter, not the date you read it.

Key milestones to track:

• Day 0: Date of denial letter (your 180-day clock starts here)
• Within 180 days: Submit first-level internal appeal with all supporting documentation
• Within 30 days of Aetna receiving your appeal: Aetna must issue its first-level decision
• After first-level denial: You may file a second-level internal appeal; Aetna applies the same 30-day decision window
• After both internal levels are exhausted: You may request independent external review through a state-certified organization or, for ERISA plans, through the federal external review process

If your situation is urgent — for example, your physician believes a delay poses a serious health risk — you can request an expedited appeal. Aetna must respond to an expedited appeal within 72 hours.

Frequently asked questions about Aetna GLP-1 appeals

Does a prior trial of Contrave or Saxenda count as step therapy under Aetna's policy?

No — Aetna's step-therapy criterion specifically requires a trial of phentermine, not anti-obesity medications in general. A documented trial of bupropion/naltrexone (Contrave) or even a prior course of Saxenda will not satisfy the phentermine requirement unless your physician explicitly documents why phentermine was contraindicated for you at the time. Your appeal must address phentermine specifically.

My BMI is 28 and I have PCOS — does that qualify me for the 27+ comorbidity pathway?

PCOS is not among the six comorbidities explicitly listed in Aetna's CPB for the lower BMI threshold. The six recognized conditions are Type 2 Diabetes, Hypertension, Dyslipidemia, Coronary heart disease, Obstructive sleep apnea, and Non-alcoholic fatty liver disease. If PCOS is your only qualifying condition, your physician should argue in the appeal letter that PCOS is closely associated with insulin resistance and metabolic syndrome — conditions that overlap with the recognized list — but approval at the discretion level is less predictable. If you also have any of the six listed conditions, even in mild form, lead with that diagnosis instead.

I completed a lifestyle program two years ago but I'm not currently enrolled. Will that satisfy Aetna's requirement?

No. Aetna's CPB requires the lifestyle modification program to be concurrent — meaning active at the time of GLP-1 initiation, not historical. Re-enroll in a structured program (a hospital-affiliated weight-management program, a dietitian-supervised plan, or a medically supervised program) and obtain dated documentation before resubmitting or filing your appeal. This is one of the most fixable denial reasons.

What does denial code N-130 mean, and do I appeal it the same way as CO-50?

N-130 (consult plan benefits) indicates that your specific plan may categorically exclude anti-obesity medications from coverage, which is a benefit design issue rather than a clinical criteria issue. A standard clinical prior-authorization appeal will not resolve a categorical benefit exclusion. Call the member services number on your insurance card, confirm whether an exclusion applies to your plan tier, and ask whether a coverage exception process exists. If your plan is employer-sponsored, your HR benefits administrator can sometimes request a plan exception.

Can Aetna deny my external review request?

Once you have exhausted both internal appeal levels, Aetna cannot block your right to independent external review under ACA Section 1557 and Aetna's own Member Rights and Responsibilities policy. The external reviewer is a neutral, state-certified organization with no financial relationship to Aetna, and its decision is binding. Studies show external reviewers overturn insurer denials in approximately 40% of cases for prescription drug coverage disputes — making it worth pursuing.

If I switch from Wegovy to Zepbound, do I need a new prior authorization?

Yes — Wegovy and Zepbound are different drugs with different NDC codes, even though both treat obesity. Each requires its own prior-authorization request, and Aetna will apply the same CPB criteria independently to each one. If you were approved for Wegovy and your physician wants to switch you to Zepbound, a new PA must be submitted. The good news is that any existing documentation of your BMI, comorbidity, and phentermine trial can be reused in the new submission.

Get a physician-ready appeal letter in 30 minutes

Writing a technically correct appeal letter — one that cites the right CPB criteria, references Garvey et al. 2023 and ADA 2025 Section 8, addresses your specific denial code, and is formatted the way Aetna's reviewers expect — takes time and medical knowledge most patients understandably don't have. PriorAuthAppeal generates a customized, physician-ready appeal letter based on your specific denial code, insurer, and clinical details for $59, with a money-back guarantee if your prescribing physician declines to sign it. That said, everything you need to write your own letter is in this guide — the criteria, the statute citations, the clinical guidelines, and the documentation checklist. Whether you use a tool or go it alone, a well-grounded appeal submitted before the 180-day deadline is the single best thing you can do after a denial.